title: Full-thickness macular hole formation in eyes with a pre-existing complete posterior vitreous detachment.
abstract: BACKGROUND
  Tangential macular traction by the posterior vitreous cortex has been widely accepted as the major causative factor in the development of idiopathic macular holes. Separation of the posterior cortical vitreous should relieve this vitreoretinal traction.
  
  
  METHODS
  The authors report five patients with idiopathic full-thickness macular hole formation that occurred in the presence of a well-documented pre-existing complete posterior vitreous detachment.
  
  
  RESULTS
  Of five eyes, three underwent pars plana vitrectomy and instillation of transforming growth factor-beta. No residual prefoveal cortical vitreous was present at the retinal surface at the time of surgery. Additionally, clinically identifiable epiretinal membranes were present in three of five eyes, but these epiretinal membranes were extremely thin, transparent, induced minimal traction, and did not warrant surgical peeling.
  
  
  CONCLUSIONS
  It is likely that, in these five patients, some mechanism other than tangential traction by prefoveal vitreous cortex is responsible for idiopathic full-thickness macular hole formation.
authors.affiliation: Retina Institute of Maryland, Baltimore 21204, USA.
authors.forename: L W
authors.initials: LW
authors.lastname: Gordon
authors.forename: B M
authors.initials: BM
authors.lastname: Glaser
authors.forename: D
authors.initials: D
authors.lastname: Ie
authors.forename: J T
authors.initials: JT
authors.lastname: Thompson
authors.forename: R N
authors.initials: RN
authors.lastname: Sjaarda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005128:Eye Diseases / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D008297:Male; D012167:Retinal Perforations / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body / Q000473:pathology*
chemical_list: D016212:Transforming Growth Factor beta